acute myeloid leukemia (AML)
Conditions
Interventions
Group A:Idarubicin 8mg/ m2, intravenously administration daily for 3 days
Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours)
Group B:Idarubicin 10mg/ m2, intravenously administration daily for 3 days
Sponsors
the First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 60 years old; 2. Able and willing to provide signed informed consent; 3. De novo AML (excluding M3); 4. Normal function of liver and kidney: serum total bilirubin <=35umol/L; AST/ALT < 2.0*upper limit of normal (ULN); 5. Normal cardiac function; 6. ECOG performance status of 0,1 or 2 (WHO standard).
Exclusion criteria
Exclusion criteria: 1. Patients who have previous chemotherapy for AML; 2. Hepatic or renal failure; 3. Uncontrolled heart failure; 4. Diagnosis of other malignant tumor meanwhile; 5. Patients with tuberculosis; 6. Secondary AML; 7. Diagnosis of other hematology diseases; 8. Pregnant or lactating females; 9. Unable to understand or to follow the reaerch protocal; 10. Known hypersensitivity or prior history of uncontrllable side effects to Daunorubicin, Idarubicin, Cytarabine or congener agents; 11. Patients aged below 18 or over 60 years old.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| desease free suvival;2-year ovrall survival;relapse free survival; | — |
Countries
China
Contacts
Public ContactDepei Wu
Outcome results
None listed